期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Fenofibrate-induced liver injury 被引量:7
1
作者 Kazufumi Dohmen Chun Yang Wen +7 位作者 Shinya Nagaoka Koji Yano Seigo Abiru toshihito ueki Atsumasa Komori Manabu Daikoku Hiroshi Yatsuhashi Hiromi Ishibashi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第48期7702-7703,共2页
Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARα, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has been frequently... Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARα, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has been frequently observed after the administration of fenofibrate and this phenomenon is considered to be non-pathological because fenofibrate activates the gene expression of the aminotransferases. Recently, fenofibrate has been used not only for hypercholesterolemia but also for primary biliary cirrhosis (PBC). However, the occurrence of liver injury induced by fenofibrate has not yet been reported written in the English literature. We herein report a rare case of liver injury due to the oral use of this drug. 展开更多
关键词 Aged FEMALE Humans LIVER Liver Cirrhosis Biliary PPAR alpha Procetofen Ursodeoxycholic Acid
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部